Collplant Biotechnologies Ltd CLGN.OQ, CLGN.O is expected to show a rise in quarterly revenue when it reports results on May 28 for the period ending March 31 2025
The Rehovot Israel-based company is expected to report a 2,599.0% increase in revenue to $2.645 million from $98 thousand a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Collplant Biotechnologies Ltd is for a loss of 4 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Collplant Biotechnologies Ltd is $14.00, above its last closing price of $1.93.
This summary was machine generated May 26 at 12:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)